A Patent for Exploring Cannabis-Infused Chewing Gum

The landscape of cannabis consumption is undergoing a profound transformation as innovative delivery methods emerge, reshaping how cannabinoids reach the user’s system. Among these innovations, cannabis-infused chewing gum has captured significant attention not only for its convenience but also for its potential in precise cannabinoid dosing and therapeutic applications. In 2025, a breakthrough patent granted by the United States Patent and Trademark Office (USPTO) marks a pivotal moment in this evolving market, enabling companies to utilize the full spectrum of cannabinoids—THC, CBD, and beyond—in specialized chewing gum formulations.

This new patent unlocks novel possibilities for edibles, emphasizing enhanced cannabinoid delivery systems through chewing gum. One company, AXIM Biotechnologies, already spearheading clinical trials with their MedChew RX product that balances THC and CBD, exemplifies the shift toward multifunctional cannabis edibles aimed at alleviating complex conditions such as muscle pain and multiple sclerosis. The protection offered by this patent not only covers existing cannabinoid-infused gums but also paves the way for future innovative recipes targeting Parkinson’s, Alzheimer’s, anxiety, and more.

As we explore this patent’s implications, a detailed examination of the science behind cannabis extraction, the mechanics of infused chewing gum delivery, and the expanding market potential will reveal why this innovation is rapidly gaining momentum. From the groundbreaking inclusion of all 85 known cannabinoids into one product, to the growing consumer demand for discreet, effective cannabis consumption options, the intersection of intellectual property and cannabis technology continues to strengthen this booming industry.

Understanding the Patent: A New Horizon for Cannabis-Infused Chewing Gum Innovation

The granting of this pivotal patent by the USPTO operates as a cornerstone for the burgeoning cannabis chewing gum sector. Unlike earlier formulations that often focused solely on isolated cannabinoids like THC or CBD, this patent authorizes the use of the entire cannabinoid profile extracted from the cannabis plant. This comprehensive scope covers approximately 85 different cannabinoids, which opens vast opportunities for product diversification and tailored therapeutic effects.

AXIM Biotechnologies’ CEO Georges Anastassov highlights the patent’s significance stating it equips the company with solid intellectual property protection, vital for modern pharmaceutical and wellness product development. The patent safeguards advanced cannabis extraction techniques and formulated delivery compositions that allow for consistent and efficient mucosal absorption of cannabinoids via chewing gum.

The patented delivery technology

At the heart of the patent lies an innovative chewing gum formulation that balances water-soluble and water-insoluble components, facilitating saliva generation and ensuring at least 10% of cannabinoids reach the oral mucosa. This delivery system is essential because it provides users rapid cannabinoid uptake bypassing certain metabolic processes that slow or reduce efficacy in traditional edible consumption. The formulation blends a base gum with cannabinoid extracts alongside flavorings, sweeteners, and fixatives to optimize both taste and cannabinoid bioavailability.

• Inclusion of full-spectrum cannabinoids: Enables nuanced formulations targeting multiple symptoms or effects simultaneously.
• Controlled cannabinoid release: Timing and dosage precision enhance therapeutic consistency.
• Enhanced mucosal delivery: Rapid absorption through oral tissues accelerates onset of benefits.
• Palatability and user experience: Flavor and texture improvements increase consumer acceptance.

The patent not only covers the composition but essentially introduces a new category within edibles by merging the convenience of gum with the medicinal potential of cannabis extracts—setting a standard for future innovations.

Exploring Diverse Cannabinoid Formulations in Chewing Gum for Targeted Therapy

With the newfound ability to incorporate all cannabinoids, manufacturers are positioned to craft highly diversified cannabis-infused chewing gums tailored for specific health benefits. This moves beyond traditional THC-dominant or CBD-focused products, enabling combinations that exploit lesser-known cannabinoids such as CBG, CBC, and CBN.

AXIM’s MedChew RX exemplifies this by integrating nearly equal parts THC and CBD within their gummy for clinical trials focused on muscle pain and multiple sclerosis management. Such formulations underline a therapeutic approach emphasizing synergies between cannabinoids instead of isolated effects.

Next-generation formulas targeting neurological disorders

Looking to the future, AXIM is developing recipes aimed at mitigating symptoms of Parkinson’s and Alzheimer’s diseases. These formulations often involve cannabinoids like CBG, known for its neuroprotective and anti-inflammatory properties, as well as THC and CBD for symptom relief.

• Parkinson’s-focused gums: Potential to reduce tremors and improve motor control through combined cannabinoid actions.
• Alzheimer’s interventions: Cannabinoid blends aimed at slowing neurodegeneration and symptomatic management.
• Anxiety and paranoia reduction: Formulas high in CBG shown to alleviate these side effects often associated with THC.
• Cancer symptom management: Multi-cannabinoid gums targeting pain, inflammation, and tumor reduction.

This degree of precision in cannabinoid content and effect unlocks new markets for medical cannabis chewing gum, reinforcing the relevance of the patent’s broad cannabinoid allowance. Moreover, it demonstrates the primary advantage of infused chewing gum as a highly adaptable delivery platform amidst growing demand for safe, controlled cannabis consumption methods.

Market Prospects and Economic Impact of Cannabis-Infused Chewing Gum

The cannabis edibles market is evolving rapidly, and chewing gum formulas fortified with a full range of cannabinoids represent a distinct growth frontier. Industry projections estimate the global cannabis-infused chewing gum market could reach approximately $4.8 billion if clinical trials underway validate efficacy and safety across various formulations.

Several drivers propel this expansion:

• Consumer preference for discreet use: Chewing gum offers a stealthy alternative to smoking or vaping, appealing to a broader demographic.
• Precision dosing and rapid onset: Saliva-mediated mucosal absorption allows users to control effects more reliably.
• Therapeutic targeting: As new cannabinoid combinations prove effective, specialised gums will touch numerous healthcare markets.
• Regulatory advancements: Patents enhance protections, encouraging investment in research and marketing efforts.

Given the complex landscape of cannabis regulations, companies leveraging this patent stand to gain a competitive edge with products designed to satisfy strict clinical standards and diverse consumer needs. The growing integration of cannabis extractions into mainstream wellness regimes will strongly benefit from the versatility and intellectual property protections this innovation provides.

Challenges and Future Directions for Cannabis-Infused Chewing Gum Development

While the patent serves as a significant leap forward, the field of cannabis-infused chewing gum faces its own challenges before fully realizing its potential. The complexity of cannabinoid chemistry and the variability in individual responses demand rigorous formulation and clinical validation. Additionally, regulatory hurdles remain a moving target, especially concerning THC content and labeling requirements.

To overcome these challenges, companies are adopting multidisciplinary approaches encompassing cannabis extraction expertise, pharmaceutical formulation, consumer sensory testing, and advanced bioavailability studies.

• Standardizing cannabinoid profiles: Ensuring consistent batch-to-batch potency.
• Optimizing flavor and texture: Improving palatability without compromising cannabinoid stability.
• Clinical efficacy trials: Demonstrating safety and targeted therapeutic benefits.
• Regulatory compliance: Navigating evolving laws and securing approvals for medical claims.

Success in tackling these issues could expand chewing gum’s role from a niche edible to a mainstream delivery system, especially in medical markets demanding precise dosing, swift action, and minimal side effects. Researchers are also examining cannabis gum’s potential for personalized medicine and combination therapies, further highlighting its promising future.

The Role of Cannabis Extraction in Advancing Infused Chewing Gum Technologies

High-quality cannabis extraction lies at the core of effective chewing gum innovation. The patent underscores advanced extraction techniques that preserve the delicate balance of cannabinoids, terpenes, and other plant constituents crucial for therapeutic efficacy and user experience. Efficient extraction not only affects product potency but also impacts flavor and safety profiles.

Recent advances include solventless and CO2 extraction methods which maintain cannabinoid purity and prevent contamination. The ability to isolate and then combine specific cannabinoids allows formulators to customize edibles in ways never before possible.

• Selective cannabinoid extraction: Targeting key compounds enhances therapeutic profiles.
• Preservation of terpene content: Retains flavor and potential entourage effects that augment cannabinoid action.
• Purity and safety assurance: Eliminates unwanted plant residues and contaminants.
• Scalability: Industrial-scale extraction meets growing market demands without compromising quality.

Effective cannabis extraction processes enable formulation scientists to deliver consistent, potent, and palatable chewing gums that meet consumer expectations for quality and medicinal value. The patent’s recognition of these techniques further validates their importance in next-generation cannabis edibles.